Meetings - The ASCO Post

Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit ma...

Supportive Care

Hematologic Malignancies

Cardio-oncology

By Chase Doyle / April 25, 2021 / 2021 ACC Conference on Advancing the Cardiovascular Care of the Oncology Patient

Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?

Given the improvements in diagnostic strategies, treatment, and supportive care, long-term survival is now an expected outcome for a large majority of patients with hematologic malignancies. Unfortuna...

Immunotherapy

Issues in Oncology

By Chase Doyle / April 10, 2021 / 2021 ACC Conference on Advancing the Cardiovascular Care of the Oncology Patient

Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

In just a few years, immunotherapy has risen to become a pillar of cancer care, leading to significantly improved response rates and even cures in previously intractable diseases. Leveraging the immun...

2021 ACC Conference on Advancing the Cardiovascular Care of the Oncology Patient

Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors

Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?

Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma